Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

Summary

This is an open labelled study. It was designed to evaluate the safety of multiple-dosing of TK006 in patients with breast cancer-related bone metastases. This trial is the extension of a core study: Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases (NCT 03239756).

Timeline

Start

2018-05

Primary completion

2019-05

Completion

2019-05

Drugs

Indications